Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon

Tavapadon, a first-in-class selective D1/D5 partial agonist, met its primary endpoint in the Phase 3 TEMPO-3 trial, significantly increasing ‘good-on-time’ in Parkinson’s disease (PD) patients.
The trial demonstrated a statistically significant increase of 1.10 hours in daily good-on-time compared to placebo (P < .001) over 26 weeks.
Key secondary outcomes showed a reduction in daily ‘off-time’ by 0.94 hours more than placebo, addressing a critical unmet need in patients with levodopa-induced motor fluctuations.
Tavapadon exhibited a favorable safety profile, with most adverse events categorized as mild to moderate, potentially avoiding some of the neuropsychiatric complications associated with traditional D2/D3-preferential agonists.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Tavapadon, a first-in-class selective D1/D5 partial agonist, met its primary endpoint in the Phase 3 TEMPO-3 trial, significantly increasing ‘good-on-time’ in Parkinson’s disease (PD) patients.
The trial demonstrated a statistically significant increase of 1.10 hours in daily good-on-time compared to placebo (P < .001) over 26 weeks.
Key secondary outcomes showed a reduction in daily ‘off-time’ by 0.94 hours more than placebo, addressing a critical unmet need in patients with levodopa-induced motor fluctuations.
Tavapadon exhibited a favorable safety profile, with most adverse events categorized as mild to moderate, potentially avoiding some of the neuropsychiatric complications associated with traditional D2/D3-preferential agonists.

Sign in free to continue reading